• Wednesday 5th February

    Pre-Conference Event [RSVP Only]

    Times (CET)

    Location: Sofitel The Grand, Amsterdam

    17:00: Opening Remarks

    Opening Remarks for the event brought to you by Cillian King, Managing Director from EQT

    17:05: Keynote - As Expected 2024 Was Damp Squib For Biotech, Will 2025 Be Better?

    Keynote session hosted by Sam Fazeli, Director of Research, Global Industries

    Bloomberg

    17:30: Conjugating Success: Innovations and Challenges in Antibody-Drug Conjugates

    Moderator: Christoph Broja, Managing Director, EQT

    Panellists:

    - Dominik Schumacher, CEO, Tubulis

    - Mark Throsby Executive Chairman, ATB Therapeutics

    - Chris Howerton PhD Chief Scientific Officer, LifeSci Advisors

    This discussion explores the dynamic landscape of antibody-drug conjugates (ADCs), focusing on current market trends, major industry deals, and technological advancements driving the field forward. Experts will examine progress in precision targeting and the innovations improving ADC efficacy and safety. The conversation will also address ongoing challenges, including issues with drug delivery, resistance mechanisms, and scalability, highlighting the areas where the field still needs to evolve to reach its full potential. The session offers a deep dive into both the breakthroughs and the hurdles shaping the future of ADCs.

    18:00 - 19:00: Networking Drinks

  • Providing VCs and Institutional Investors access to 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.

  • Organised by EQT Life Sciences

    EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform.
    As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

    The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek.
    EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.
    broken image
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More